SHC Stock Analysis: Buy, Sell, or Hold?
SHC - Sotera Health Company Common Stock
$18.17
-0.25 (-1.36%)
▼
5d:
+1.74%
30d:
+11.68%
90d:
+18.29%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 14, 2026
Get Alerted When SHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SHC shows positive signals but monitor for confirmation. Market pricing in 1.6% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: SHC shows positive signals but monitor for confirmation. Market pricing in 1.6% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$24.11
Based on 6.8% avg growth
INTRINSIC VALUE TODAY
$14.97
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SHC is currently trading at $18.17, which is considered extended relative to its 30-day fair value range of $15.88 to $17.82. The stock's valuation (Forward PE: 17.1) is in line with its historical norms (16.3). At these levels, the market is pricing in 1.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SHC is in a strong uptrend. The price is approaching resistance at $16.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SHC has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.22 (+11.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SHC is in a strong uptrend. The price is approaching resistance at $16.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SHC has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.22 (+11.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$15.88 -
$17.82
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.5%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($20.22)
- NEUTRAL: Market pricing in 1.6% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$15.88 -
$17.82
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$14.79
Resistance Level
$16.58
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.09
Wall Street Target
$20.22
(+11.3%)
Revenue Growth (YoY)
10.0%
Earnings Growth (YoY)
175.4%
Profit Margin
9.9%
Valuation Premium vs History
+1.6% premium
PE vs Historical
17.1 vs 16.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.6%
(market-implied from PE analysis)
1-Year Target
$18.46
(+2%)
2-Year Target
$18.76
(+3%)
3-Year Target
$19.06
(+5%)
3-Yr Target (if PE normalizes)
(PE: 17→16)
PE COMPRESSION
$18.17
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 9.7%)
$30.54
(+68%)
Base:
(SPY PE: 17.1, Growth: 9.7%)
$23.96
(+32%)
Bear:
(PE: 14.5, Growth: 9.7%)
$20.37
(+12%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (43x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 42.77 | Current EPS (TTM): $0.43
Bull Case
$40.46
(+120%)
Analyst growth 100.0%, PE expands to 47.0
Base Case
$36.78
(+100%)
Market implied 100.0%, PE stable at 42.8
Bear Case
$12.51
(-32%)
Severe decline -20.0%, PE contracts to 36.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 13, 2026 5:47 PM ET
Data refreshes hourly during market hours. Next update: 6:47 PM
Data refreshes hourly during market hours. Next update: 6:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Gtcr Investment Xi Llc
SELL
10000000 shares
2026-03-06
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$591 | 64 BUY |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$242 | 67 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$157 | 60 BUY |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$271 | 54 HOLD |
